Direct costs in patients with nonvalvular atrial fibrillation newly indicated to apixaban: a retrospective-prospective single-arm cohort study

Abstract

Atrial fibrillation (AF) affects 46.3 million people; its prevalence has tripled over the last 50 years. AF leads to formation of blood clots increasing four-fold the risk of a stroke.

Preventive anticoagulant therapy with warfarin has been well established for over 50 years but has efficacy and safety limitations. New anticoagulants do not require laboratory monitoring of prothrombin time, have low risk of adverse events, yet are more costly.

Keywords

• anticoagulation
• atrial fibrillation
• direct costs
• apixaban
• warfarin
• bleeding
• real world evidence